Nanoform signs GMP manufacturing program with TargTex following formulation success
Nanoform (Finland), an innovative nanoparticle medicine enabling company, today announced it has signed a GMP1 manufacturing program (clinical development) to enhance TargTex’s Glioblastoma multiforme drug candidate. The program starts with a PoP (Proof of Process) phase.
This follows a successful PoC (Proof of Concept) study where the hydrogel formulation developed by Nanoform (CESS®2 technology-based nanoparticles) enabled a fivefold increase in drug load compared to nanomilling, the less effective alternative.
TargTex, a European biotech company, is developing an innovative hydrogel based pharmaceutical product for a highly unmet medical need: Glioblastoma multiforme (GBM) treatment. About 3 in 100,000 people develop the disease each year. GBM is the most aggressive type of cancer that begins within the brain and there is as of yet no efficacious treatment for this deadly disease. TargTex’s drug candidate has already shown efficacy in animal models.
The value of the GMP and non-GMP (PoP) projects are according to Nanoform’s guided business model, €0.5m to €10m per GMP project and €0.05m to €0.5m per non-GMP project. The value of the today announced PoP and GMP contract is low seven figures (€).
Christian Jones, CCO of Nanoform, commented: “We are delighted to announce the successful progression into PoP and GMP manufacturing of TargTex’s GBM program. We are pleased to have played a key role in the development of this unique formulation using our proprietary technology and formulation expertise, which has enabled effective drug delivery and will bring hope to brain cancer patients globally.”
